Joanne Filicko
Thomas Jefferson University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Joanne Filicko.
Bone Marrow Transplantation | 2003
Joanne Filicko; Hillard M. Lazarus; Neal Flomenberg
Summary:Hematopoietic progenitor cell transplantation is often associated with severe mucosal toxicity. The need for parenteral analgesics and parenteral nutrition are evidence of the severity of the problem in individual patients. However, the increased risk for systemic infection related to bacteremia associated with the breakdown of mucosal barriers is a significant cause of morbidity and mortality as well. There is a multitude of grading scales, demonstrating the lack of consensus among clinicians in this area. Multiple agents have been used prophylactically and therapeutically to address mucositis. While efforts have been less successful in the past, the advent of newer agents including amifostine, keratinocyte growth factor, transforming growth factor beta and interleukin-11 provides hope that this toxicity will be significantly decreased in the near future.
Journal of General Virology | 2009
A. V. Joshi; Jie Tang; Melanie Kuzma; John L. Wagner; Bijoyesh Mookerjee; Joanne Filicko; Matthew Carabasi; Neal Flomenberg; Phyllis Flomenberg
Donor lymphocytes have potential as a treatment for adenovirus (Ad) disease in haematopoietic stem cell transplant (SCT) recipients, but better understanding of Ad-specific T-cell responses is required. Most healthy adults exhibit memory T-cell responses to hexon, a capsid protein synthesized late after infection. However, since the Ad E3-19k downregulates major histocompatibility complex (MHC) class I molecules, cytotoxic T cells (CTLs) targeted to early viral proteins may be more effective in eliminating Ad-infected cells in vivo. Here we show that Ad-specific CTLs recognize the early region 2 proteins DNA polymerase (Pol) and DNA-binding protein (DBP). Firstly, memory Ad-specific CD8(+) T cells were amplified from healthy donors by in vitro stimulation with Ad-infected dendritic cells and found to exhibit MHC-restricted cytotoxicity to targets expressing Pol and DBP. Secondly, gamma interferon responses to HLA A2-binding motif peptides from Pol and DBP were directly detected in peripheral blood mononuclear cells (PBMCs) from a recently infected normal donor. Peptide-specific CTLs generated to Pol and DBP epitopes were confirmed to exhibit HLA A2-restricted killing of targets expressing Pol or DBP. Lastly, Pol-epitope-specific T cells were detected at similar or higher frequencies than hexon and DBP in three of three SCT recipients recovering from invasive Ad disease. Pol epitopes were well conserved among different Ad serotypes. Therefore, Pol is a promising target for immunotherapy of Ad disease.
Bone Marrow Transplantation | 2004
Gordon L. Phillips; Barry Meisenberg; Donna Reece; V. R. Adams; Ashraf Badros; Janet Brunner; R Fenton; Joanne Filicko; D. L. Grosso; Greg A. Hale; Dianna Howard; V. P. Johnson; Ab Kniska; K. W. Marshall; B. Mookerjee; R. Nath; Aaron P. Rapoport; Clarence Sarkodee-Adoo; N Takebe; D. H. Vesole; John L. Wagner; Neal Flomenberg
Summary:High-dose chemotherapy using melphalan (HDMEL) is an important component of many conditioning regimens that are given before autologous hematopoietic stem cell transplantation (AHSCT). In contrast to the situation in myeloma, and to a lesser degree acute leukemia, only a very limited published experience exists with the use of HDMEL conditioning as a single agent in doses requiring AHSCT for lymphoma, both Hodgkin lymphoma (HL) and especially non-Hodgkin lymphoma (NHL). Thus, we report results of treating 26 lymphoma patients (22 with NHL and four with HL) with HDMEL 220–300 mg/m2 plus amifostine (AF) cytoprotection and AHSCT as part of a phase I–II trial. Median age was 51 years (range 24–62 years); NHL histology was varied, but was aggressive (including transformed from indolent) in 19 patients, indolent in two patients and mantle cell in one. All 26 patients had been extensively treated; 11 were refractory to the immediate prior therapy on protocol entry and two had undergone prior AHSCT. All were deemed ineligible for other, ‘first-line’ AHSCT regimens. Of these 26 patients, 22 survived to initial tumor evaluation on D +100. At this time, 13 were in complete remission, including four patients who were in second CR before HDMEL+AF+AHSCT. Responses occurred at all HDMEL doses. Currently, seven patients are alive, including five without progression, with a median follow-up in these latter patients of D +1163 (range D +824 to D +1630); one of these patients had a nonmyeloablative allograft as consolidation on D +106. Conversely, 14 patients relapsed or progressed, including five who had previously achieved CR with the AHSCT procedure. Two patients, both with HL, remain alive after progression; one is in CR following salvage radiotherapy. Six patients died due to nonrelapse causes, including two NHL patients who died while in CR. We conclude that HDMEL+AF+AHSCT has significant single-agent activity in relapsed or refractory NHL and HL. This experience may be used as a starting point for subsequent dose escalation of HDMEL (probably with AF) in established combination regimens.
Case Reports in Oncology | 2017
Jonathan Pan; Jason Chen; Joanne Filicko; Dolores Grosso; Michelle Nagurney; Onder Alpdogan; Neal Flomenberg
Although rare, both central nervous system and pericardial involvement of myeloma have been well described in the literature. Their simultaneous occurrence in relapsed disease, however, has not been previously reported. This case describes a 54-year-old female who was treated for high-risk multiple myeloma with multiregimen chemotherapy and allogeneic hematopoietic stem cell transplantation. Four months after transplant, she was found to have relapsed disease manifesting as an extraosseous, intracranial plasmacytoma and simultaneous malignant pericardial effusion. Her disease characteristics, treatment course, radiologic and pathologic findings are described in detail, and we review the previous literature to determine the various aspects of her disease that may have contributed to her aggressive clinical course.
Biology of Blood and Marrow Transplantation | 2007
Dionissios Neofytos; Ambrish Ojha; Bijoyesh Mookerjee; John L. Wagner; Joanne Filicko; Andres Ferber; Scott K. Dessain; Dolores Grosso; Janet Brunner; Neal Flomenberg; Phyllis Flomenberg
Biology of Blood and Marrow Transplantation | 2004
Gordon L. Phillips; Barry Meisenberg; Donna Reece; V. R. Adams; Ashraf Badros; Janet Brunner; R Fenton; Joanne Filicko; Dolores Grosso; Greg A. Hale; Dianna Howard; V. P. Johnson; A. Kniska; K. W. Marshall; R. Nath; E. Reed; Aaron P. Rapoport; Naoko Takebe; David H. Vesole; John L. Wagner; Neal Flomenberg
Biology of Blood and Marrow Transplantation | 2001
Thea M. Friedman; Gabor Varadi; Deborah D Hopely; Joanne Filicko; John E. Wagner; Andres Ferber; Jose Martinez; Janet Brunner; Dolores Grosso; Liza McGuire; Robert Korngold; Neal Flomenberg
Biology of Blood and Marrow Transplantation | 2005
Irina Kakhniashvili; Joanne Filicko; Walter K. Kraft; Neal Flomenberg
Seminars in Oncology | 2004
Dolores Grosso; Joanne Filicko; Guillermo Garcia-Manero; Frank V. Beardell; Janet Brunner; Jeffrey Cohn; Andres Ferber; Jose Martinez; Bijoyesh Mookerjee; Lewis Rose; David S Tice; John L. Wagner; Robert Capizzi; Neal Flomenberg
Biology of Blood and Marrow Transplantation | 2006
Joanne Filicko; Dolores Grosso; Phyllis Flomenberg; Janet Brunner; Scott K. Dessain; William R. Drobyski; Andres Ferber; Thea M. Friedman; I. Kahkniashvili; Carolyn A. Keever-Taylor; Bijoyesh Mookerjee; John L. Wagner; Robert Korngold; Neal Flomenberg